Abstract
In patients with diabetes, hyperglycemia is known to promote high levels of diacylglycerol which activates protein kinase C (PKC) in the vascular tissues and leads to the production of vascular endothelial growth factor (VEGF) in the retina. PKC activation and increased concentration of VEGF are likely to play a key role in diabetic microvascular complications, particularly change in vascular permeability, inflammation, fluid leakage and ischemia in the retina. PKC comprises a super family of isoenzymes that is activated in response to various stimuli. The PKC family consists of 12 isomers that possess distinct differences in structure, substrate requirement, expression and localization. PKC isomer selective inhibitors and VEGF trap are likely to be new therapeutics, which can delay the onset or stop the progression of diabetic vascular disease. A new promising therapy for diabetic retinopathy is undergoing Phase III trials, in which they proposed to target PKC βII isomer using Ruboxistaurin by oral administration. Besides retina, PKC βII isomer is found in higher concentration in brain, spleen, etc. So, oral targeting may be a questionable approach since generalized inhibitors may prove toxic in the treatment of diabetic retinopathy and ocular delivery may be a better alternative approach.
Keywords: Diabetic Retinopathy, PKC, VEGF, inhibitors, novel drug delivery approach
Current Drug Delivery
Title:Oral Targeting of Protein Kinase C Receptor: Promising Route for Diabetic Retinopathy?
Volume: 9 Issue: 4
Author(s): Deepa Pathak, Ankur Gupta, Bhagyashree Kamble, Gowthamarajan Kuppusamy and Bhojraj Suresh
Affiliation:
Keywords: Diabetic Retinopathy, PKC, VEGF, inhibitors, novel drug delivery approach
Abstract: In patients with diabetes, hyperglycemia is known to promote high levels of diacylglycerol which activates protein kinase C (PKC) in the vascular tissues and leads to the production of vascular endothelial growth factor (VEGF) in the retina. PKC activation and increased concentration of VEGF are likely to play a key role in diabetic microvascular complications, particularly change in vascular permeability, inflammation, fluid leakage and ischemia in the retina. PKC comprises a super family of isoenzymes that is activated in response to various stimuli. The PKC family consists of 12 isomers that possess distinct differences in structure, substrate requirement, expression and localization. PKC isomer selective inhibitors and VEGF trap are likely to be new therapeutics, which can delay the onset or stop the progression of diabetic vascular disease. A new promising therapy for diabetic retinopathy is undergoing Phase III trials, in which they proposed to target PKC βII isomer using Ruboxistaurin by oral administration. Besides retina, PKC βII isomer is found in higher concentration in brain, spleen, etc. So, oral targeting may be a questionable approach since generalized inhibitors may prove toxic in the treatment of diabetic retinopathy and ocular delivery may be a better alternative approach.
Export Options
About this article
Cite this article as:
Pathak Deepa, Gupta Ankur, Kamble Bhagyashree, Kuppusamy Gowthamarajan and Suresh Bhojraj, Oral Targeting of Protein Kinase C Receptor: Promising Route for Diabetic Retinopathy?, Current Drug Delivery 2012; 9 (4) . https://dx.doi.org/10.2174/156720112801323080
DOI https://dx.doi.org/10.2174/156720112801323080 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chronic Hepatitis C, Insulin Resistance and Vascular Disease
Current Pharmaceutical Design Demonstration of the Efficacy of Statins in Resolution of Plaque Inflammation by Serial FDG Imaging
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Adiponectin and its Role in Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Nitric Oxide and its Antithrombotic Action in the Cardiovascular System
Current Drug Targets - Cardiovascular & Hematological Disorders An Overview: Current Systemic Therapies for Advanced Non-Small Cell Lung Cancer
Current Respiratory Medicine Reviews Adverse Cardiovascular Effects of Antirheumatic Drugs: Implications for Clinical Practice and Research
Current Pharmaceutical Design More Effective DPP4 Inhibitors as Antidiabetics Based on Sitagliptin Applied QSAR and Clinical Methods
Current Computer-Aided Drug Design Tangier Disease Four Decades of Research: A Reflection of the Importance of HDL
Current Medicinal Chemistry Therapeutic Potential of Nucleic Acid-Based Drugs in Coronary Hyper- Proliferative Vascular Diseases
Current Medicinal Chemistry Translational Pharmacology in Aging Men with Benign Prostatic Hyperplasia: Molecular and Clinical Approaches to Alpha1-Adrenoceptors
Current Aging Science Should Adipokines be Considered in the Choice of the Treatment of Obesity-Related Health Problems?
Current Drug Targets Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG
Current Vascular Pharmacology Recent Advances and Patents on Nanoscale Systems and Triggerable Drug Delivery in Medical Devices
Recent Patents on Biomedical Engineering (Discontinued) Effects of Maternal Obesity on Maternal and Fetal Health
Current Women`s Health Reviews The Role of AGEs in Cardiovascular Disease
Current Pharmaceutical Design How Cardiomyocytes Make the Heart Old
Current Pharmaceutical Biotechnology Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz
Current HIV Research Meet Our Editorial Board Member:
Reviews on Recent Clinical Trials Systemic Adverse Drug Reactions Secondary to Anti-VEGF Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration
Current Vascular Pharmacology Halving Your Cake and Eating it, Too: A Case-based Discussion and Review of Metabolic Rehabilitation for Obese Adults with Diabetes
Current Diabetes Reviews